Previous 10 | Next 10 |
2023-03-22 04:40:44 ET The U.S. Food and Drug Administration (FDA) approved Novartis' ( NYSE: NVS ) citrate-free high-concentration formulation (HCF) of Hyrimoz, a biosimilar to AbbVie's ( NYSE: ABBV ) blockbuster drug Humira. Hyrimoz (adalim...
2023-03-21 09:53:00 ET Growing one's wealth in the stock market is simple, at least in theory. All that's needed are time, the right investments, and the patience to hold shares of companies even during downturns. But in practice, it isn't always easy to pull that off. The tendency to panic...
2023-03-20 00:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-17 05:45:02 ET The U.S. Food and Drug Administration (FDA) approved the expanded use of Novartis' ( NYSE: NVS ) Tafinlar plus Mekinist to treat children one year of age and older with low-grade glioma (LGG) having a BRAF V600E mutation, requiring systemic therapy. ...
2023-03-14 09:00:01 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for tho...
2023-03-14 06:50:07 ET Novartis ( NYSE: NVS ) is starting the sale of some of its ophthalmology assets as it plans to focus more on its core areas, Bloomberg News reported, citing people familiar with the matter. The assets include, dry eye therapy Xiidra, which saw s...
2023-03-13 04:53:55 ET Novartis ( NYSE: NVS ) started a new stock buyback program to repurchase up to CHF10B ($10.9B) worth of its shares across three years, Reuters reported. The Swiss pharma giant plans to purchase up to 10% of its shares from March 7, 2023 (the date of ...
2023-03-12 10:00:00 ET Biosimilar medication, generic versions of typically expensive biologic-based drugs, are set to save patients and the health care system $180B over the next five years as even more hit the market. New launches and an expected increase in uptake of biosimilars ...
2023-03-10 15:11:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the current economic climate of rising interest rates, persistent inflation, simmering geopolitical risks and looming recessionary threats, it’s crucial to prioritize quality, safety ...
2023-03-10 11:19:47 ET Olema Oncology ( NASDAQ: OLMA ) will let go of ~25% of its employees across research, early development, and general and administrative functions as part of a restructuring. The move is being done so the company can focus on late-stage development of...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...